Tags

Type your tag names separated by a space and hit enter

Epigenetic Drug Repositioning for Alzheimer's Disease Based on Epigenetic Targets in Human Interactome.
J Alzheimers Dis 2018; 61(1):53-65JA

Abstract

BACKGROUND

Epigenetics has emerged as an important field in drug discovery. Alzheimer's disease (AD), the leading neurodegenerative disorder throughout the world, is shown to have an epigenetic basis. Currently, there are very few effective epigenetic drugs available for AD.

OBJECTIVE

In this work, for the first time we have proposed 14 AD repositioning epigenetic drugs and identified their targets from extensive human interactome.

METHODS

Interacting partners of the AD epigenetic proteins were identified from the extensive human interactome to construct Epigenetic Protein-Protein Interaction Network (EP-PPIN). Epigenetic Drug-Target Network (EP-DTN) was constructed with the drugs associated with the proteins of EP-PPIN. Regulation of non-coding RNAs associated with the target proteins of these drugs was also studied. AD related target proteins, epigenetic targets, enriched pathways, and functional categories of the proposed repositioning drugs were also studied.

RESULTS

The proposed 14 AD epigenetic repositioning drugs have overlapping targets and miRs with known AD epigenetic targets and miRs. Furthermore, several shared functional categories and enriched pathways were obtained for these drugs with FDA approved epigenetic drugs and known AD drugs.

CONCLUSIONS

The findings of our work might provide insight into future AD epigenetic-therapeutics.

Authors+Show Affiliations

Department of Biophysics, Bose Institute, West Bengal, India.Department of Biophysics, Bose Institute, West Bengal, India.School of Electrical and Computer Engineering, Purdue University, West Lafayette, IN, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29199645

Citation

Chatterjee, Paulami, et al. "Epigenetic Drug Repositioning for Alzheimer's Disease Based On Epigenetic Targets in Human Interactome." Journal of Alzheimer's Disease : JAD, vol. 61, no. 1, 2018, pp. 53-65.
Chatterjee P, Roy D, Rathi N. Epigenetic Drug Repositioning for Alzheimer's Disease Based on Epigenetic Targets in Human Interactome. J Alzheimers Dis. 2018;61(1):53-65.
Chatterjee, P., Roy, D., & Rathi, N. (2018). Epigenetic Drug Repositioning for Alzheimer's Disease Based on Epigenetic Targets in Human Interactome. Journal of Alzheimer's Disease : JAD, 61(1), pp. 53-65. doi:10.3233/JAD-161104.
Chatterjee P, Roy D, Rathi N. Epigenetic Drug Repositioning for Alzheimer's Disease Based On Epigenetic Targets in Human Interactome. J Alzheimers Dis. 2018;61(1):53-65. PubMed PMID: 29199645.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Epigenetic Drug Repositioning for Alzheimer's Disease Based on Epigenetic Targets in Human Interactome. AU - Chatterjee,Paulami, AU - Roy,Debjani, AU - Rathi,Nitin, PY - 2017/12/5/entrez PY - 2017/12/5/pubmed PY - 2018/7/14/medline KW - Alzheimer’s disease KW - combined interactome KW - epigenetic drug repositioning KW - epigenetic drug targets KW - epigenetic drug-target network KW - epigenetic protein-protein interaction network KW - epigenetics KW - pathway enrichment analysis SP - 53 EP - 65 JF - Journal of Alzheimer's disease : JAD JO - J. Alzheimers Dis. VL - 61 IS - 1 N2 - BACKGROUND: Epigenetics has emerged as an important field in drug discovery. Alzheimer's disease (AD), the leading neurodegenerative disorder throughout the world, is shown to have an epigenetic basis. Currently, there are very few effective epigenetic drugs available for AD. OBJECTIVE: In this work, for the first time we have proposed 14 AD repositioning epigenetic drugs and identified their targets from extensive human interactome. METHODS: Interacting partners of the AD epigenetic proteins were identified from the extensive human interactome to construct Epigenetic Protein-Protein Interaction Network (EP-PPIN). Epigenetic Drug-Target Network (EP-DTN) was constructed with the drugs associated with the proteins of EP-PPIN. Regulation of non-coding RNAs associated with the target proteins of these drugs was also studied. AD related target proteins, epigenetic targets, enriched pathways, and functional categories of the proposed repositioning drugs were also studied. RESULTS: The proposed 14 AD epigenetic repositioning drugs have overlapping targets and miRs with known AD epigenetic targets and miRs. Furthermore, several shared functional categories and enriched pathways were obtained for these drugs with FDA approved epigenetic drugs and known AD drugs. CONCLUSIONS: The findings of our work might provide insight into future AD epigenetic-therapeutics. SN - 1875-8908 UR - https://www.unboundmedicine.com/medline/citation/29199645/Epigenetic_Drug_Repositioning_for_Alzheimer's_Disease_Based_on_Epigenetic_Targets_in_Human_Interactome_ L2 - https://content.iospress.com/openurl?genre=article&id=doi:10.3233/JAD-161104 DB - PRIME DP - Unbound Medicine ER -